Objective To prepare transferrin and Arg-Gly-Asp polypeptide co-modified nanoparticles(TF/RGD-NPs)and evaluate its targeting efficiency to melanoma.Methods The co-modified nanoparticles were prepared by emulsion method and its appearance,particle size and Zeta potential were evaluated.The cellular uptake experiment and melanoma tumor spheroids penetration test were used to evaluate the affinity and ability to penetrate tumor tissues of TF/RGD-NPs to melanoma B16 cells. Results The particle diameter of co-modified nanoparticles was(113.4 ±12.5)nm and the Zeta potential was(4.53 ±2.15)mV.In vitro uptake test demonstrated that the efficacy of cellular uptaken TF/RGD-NPs by B16 cells were 2.7 times and 2.9 times to TF-NPs and RGD-NPs,respectively,the differences were all significant(P<0.05 ).Tumor spheroid penetration test results showed that TF/RGD-NPs has good affinity to melanoma cells.Conclusion TF/RGD-NPs can target to melanoma B16 cell efficiency in vitro,it may be serve as a potential drug delivery system for targeting melanoma.

Objective To explore the effect of X-linked inhibitor of apoptosis protein(XIAP)combined with doxorubicin on the proliferation of MCF-7 cell and growth of MCF-7 bearing nude mice.Methods The anti-proliferation efficiency of doxorubicin and embelin were determined by MTT assay.MCF-7 cell apoptosis induced by embelin and doxorubicin were detected by Flow cytometry.Anti-tumor ability of embelin and doxorubicin were evalued with tumor spheroids test.MCF-7 cell were xenografted to mice to establish the animal model,which was used to evaluate the effect of anti-tumor. Results Compared with saline group,embelin group and doxorubicin group,the combination(doxorubicin +embelin)group inhibited the growth of MCF-7 cells effectively(P<0.01).The combination group induced the apoptosis of MCF-7 cells more effectively than doxorubicin alone(P<0.01), and significantly inhibit the growth of tumor in vitro and in vivo than other groups(P<0.01).Conclusion The combination of doxorubicin and embelin may be used as a potentially effective treatment method for breast cancer.

Antineoplastic Combined Chemotherapy Protocols ; therapeutic use ; Cisplatin ; administration & dosage ; Drug Therapy, Combination ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Fluorouracil ; administration & dosage ; Humans ; Intestinal Neoplasms ; drug therapy ; Lung Neoplasms ; drug therapy ; Male ; Phytotherapy ; Tetrahydrofolates ; administration & dosage

12E7 Antigen ; Adult ; Antigens, CD ; metabolism ; Cell Adhesion Molecules ; metabolism ; Desmin ; metabolism ; Desmoplastic Small Round Cell Tumor ; metabolism ; pathology ; surgery ; Diagnosis, Differential ; Female ; Humans ; Neoplasm Recurrence, Local ; Neuroblastoma ; metabolism ; pathology ; Ovarian Neoplasms ; metabolism ; pathology ; surgery ; Phosphopyruvate Hydratase ; metabolism ; Rhabdomyosarcoma, Embryonal ; metabolism ; pathology ; Sarcoma, Ewing ; metabolism ; pathology ; Vimentin ; metabolism

Objective To evaluate the effect of biofeedback therapy for the treatment of myogenic fecal incontinence. MethodsA general assessment about anorectal function was made on 17 cases receiving biofeedback therapy including muscle power training,sensory training and coordination training. Results The clinical scores before and after biofeedback therapy were 1.66?0.23,3.80?0.42 respectively,with an effective rate of 82%. The anus maximum contracting pressure elevated,(73?20) mm Hg vs. (123?30) mm Hg; myoelectric amplitude increased,(122?32) ?V vs. (230?41) ?V;Contracting time prolonged,(4.1?2.0) s vs. (9.4?3.0) s; The sensory threshold was lowered,(50?12) ml vs. ( 20? 10) ml;The feel-contract time increased,(3.1?0.4) s vs. (1.2?0.3) s. Positive rectal contraction reflex was seen in 41% patients before therapy compared with 82% after therapy. Conclusions Biofeedback therapy increases contractility of sphincter,decreases threshold of rectal sensory,and is a therapy of choice for myogenic fecal incontinence.

Cardiomyopathy, Dilated ; genetics ; Lamin Type A ; genetics

Female ; Humans ; Male ; Sepsis ; complications ; Wernicke Encephalopathy ; diagnosis

Anemia, Hemolytic ; chemically induced ; therapy ; Female ; Humans ; Paraquat ; poisoning ; Poisoning ; therapy ; Young Adult

Cardiomyopathy, Dilated ; genetics ; Humans ; NAV1.5 Voltage-Gated Sodium Channel ; Sodium Channels ; genetics

Objective To investigate the effect of pre-emptive intrathecal (IT) administration of L-NAME, a non-selective nitric oxide synthase (NOS) inhibitor on calcitonin gene-related peptide (CGRP) expression in the dorsal horn of spinal cord in a rat model of neuropathic pain. Methods Ninety-six female adult SD rats weighing 220-310 g were randomly divided into four groups with 24 animals in each group : group A received IT 0.9% NaCl 15 min before sham operation; group B received IT 0.9% NaCl 15 min before right sciatic nerve ligation; group C received IT L-NAME 250 mg in 10?l 15 min before sham operation and group D received IT L-NAME 250 ?g in 10 ?l15 min before sciatic nerve ligation. The animals were anesthetized with intraperitoneal pentobarbital 50 mg?kg-1. A PE-10 catheter was placed in subarachnoid space with the tip of the catheter reaching the lumbar enlargement region. The animals were allowed to recover for 3-4 days and only those waking normally were used in the study. Right sciatic nerve was exposed and four loose ligatures were placed on the sciatic nerve according to the method described by Bennet. In sham operation the sciatic nerve was exposed but not ligated. The animals were sacrificed on the 1 st, 4 th, 7 th and 14 th day after operation. The lumbar segment of spinal cord was immediately removed. The CGRP expression in the ligated-side dorsal horn was assessed with immuno-histochemistry technique. Results In group B and D CGRP expression in the ligated side dorsal horn was significantly increased on the 4th, 7th and 14th day after operation as compared with that in group A. There was no significant difference in the CGRP expression in the ligated side dorsal horn between group A and C as well as between B and D. Conclusion Pre-emptive IT administration of L-NAME cannot inhibit the increase in CGRP expression in dorsal horn induced by peripheral nerve injury, suggesting that the neuropathic pain mediated by NO is not related to the release of calcitonin gene-related peptide.